Markets
JNJ

Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention

Amgen, Inc . AMGN announced that the FDA has approved its regulatory application seeking approval to include data from the cardiovascular outcomes study, FOURIER, on the label of its PCSK9 inhibitor, Repatha.

With the label expansion, Repatha can now be prescribed to prevent heart attacks, strokes and coronary revascularizations in patients with established cardiovascular disease.

This year so far, Amgen's shares are up 21.2%, better than 2.6% increase registered by the industry .

Data from the phase IIIFOURIER study, presented in the first quarter, had revealed significant reduction in myocardial infarctions and strokes on treatment with Repatha compared with the current best therapy alone.

Repatha significantly reduced risk of hard MACE (heart attack, stroke or cardiovascular death) by 20% compared to the standard treatment with statin therapy. For individual components, risks of heart attack, stroke and coronary revascularization were nominally reduced by 27%, 21% and 22%, respectively, with Repatha.

However, Repatha did not show any improvement in cardiovascular death risk, which had raised investor concerns then.

Notably, Repatha gained an FDA approval in August 2015, for the treatment of patients, incapable of managing their LDL cholesterol at acceptable levels. It is approved in over 50 countries, including the United States, Japan, Canada and overall, 28 member countries of the European Union for the given indication.

However, uptake of the drug has not been very encouraging so far due to higher pricing and re-imbursement issues/payer restrictions. Sanofi SNY and partner Regeneron Pharmaceuticals, Inc. REGN also faced similar issues with their PCSK9 inhibitor, Praluent.

The FOURIER data holds the key to the commercial success of Repatha as it will broaden the use of the drug. With the cardiovascular indication approved to be included in Repatha's label, patient access to the drug should improve.

Amgen filed regulatory applications in both the United States and EU to include FOURIER data on Repatha's label in June 2017. In July, the FDA had granted priority review forthe regulatory application.

Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

A better-ranked large-cap pharma stock is Johnson & Johnson JNJ , which has a Zacks Rank #2 (Buy).

Shares of J&J have risen 21.5% this year so far while 2018 earnings estimates have gone up 0.7% in the past 60 days.

Zacks' Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.

Click here for Zacks' private trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

JNJ REGN SNY AMGN

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More